Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B

Novo Nordisk announced a 10% increase in sales, with its obesity care segment reaching DKK 82 billion, indicating significant growth in the pharmaceutical company's key areas.